Throughout the study, the same densitometer was used at each of the two centers to optimize the measurements.A phantom spine was scanned on a minimum of dwk in each center to ensure precision over time.Serum and urine samples were collected at baseline and at, and mo for the estimation of bone alkaline phosphatase, the second voided urine of the day was collected and the concentration of uNTX was expressed as a ratio to urinary creatinine.Full local ethics committee approval was successfully obtained in both centers recruiting patients for the study.Compliance of study medication was discussed at each study visit and the number of missed doses was recorded.To allow for a dropout rate, patients were recruited to ensure adequate numbers at the end of the study.When the required osteopenic patients were recruited, no further patients were recruited to the study.BMD changes from baseline at the LS and TH for the and y followup visits were normally distributed and thus expressed as percentages with confidence intervals.Comparison between groups was done using the independentsamplesttest.The bone biomarker data changes on study were also normally distributed and expressed as a mean percentage change from baseline.Comparisons at each time point were expressed graphically using confidence intervals.Statistical analysis between the two groups was done using the independentsamplesttest.Both Spermine companies were kept informed of the progress of the study but had no involvement in the analysis or interpretation of the results Curcumin presented.A total of recruited patients were identified as having osteopenia at the time of the baseline scan.Sixtyeight of the remaining patients had normal BMD and already had osteoporosis before starting anastrozole.Patients with normal BMD were on average younger and had a higher body mass index than the osteopenic and osteoporotic patients.In the randomized population of women with osteopenia, the baseline characteristics were similar between the group allocated to ibandronate and those allocated to placebo.Two patients, both receiving ibandronate, requested withdrawal from the study before the year visit due to side effects from their anastrozole tablets. In both these cases, no follow up BMD data were available.after years. In the anastrozole plus placebo group, mean declines in BMD were observed at and years both at the LS and TH. The differences between the two treatment arms were statistically significant at both sites and at each time point. After years, five osteopenic patients receiving anastrozoleplusplacebo deve loped osteoporosis and wereof fered bisphosphonate treatment.Six patients who were osteopenic at baseline lost greater than BMD at either their LS or TH following years of treatment with ibandronate.In each of these cases, the bone loss occurred at only one of the measured sites. Patients treated with ibandronate were more likely to achieve significant gains in LS and TH BMD compared with those treated with placebo, respectively, after years.Bone turnover markers also provide an indirect assessment of treatment compliance.Seventyfour percent of those taking ibandronate had a decrease in NTX of. This contrasts with only of those taking placebo and in whom had a increase in NTX.The number of patients suffering joint pains was similar in each of the randomized groups.